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ENTRY INHIBITORS
HIV infection of new human target cells is a process involving 
complex interactions between both viral and human receptors,
resulting in fusion of viral and cellular membranes. There are
at least three components of the initial HIV entry process,
shown in Fig. IA: viral-cell attachment, mediated by
interaction between viral gp120 and host cell CD4;
attachment of gp120 to either or both CCR5, CXCR4 co-
receptors; and approximation and fusion of target cell and
viral membranes by conformational changes in the bridging
trans-membrane protein gp41, due to cross linking of two
helical regions (HR1 and HR2) of gp41. 
Compounds inhibiting each of these processes are at varying
stages of development. All three targets have promising
agents, with demonstrated ARV activity with mechanisms of
action as shown in Fig. IB. While there is considerable clinical
experience with the fusion inhibitor (T-20), which was
registered for use in the USA and Europe in 2003, attachment
inhibitors are at a very much earlier stage of development.
Inhibitors of the human CCR5 co-receptor are unique among
ARVs because their targets are encoded by human rather than
the more mutation-prone HIV-genome.
CD4 ATTACHMENT INHIBITORS
PRO 542 is fusion protein (CD4-IgG2 tetramer), which binds to
gp120, inhibits gp120/CD4 attachment, and has broad in vitro
antiviral activity independent of co-receptor usage or
resistance to existing classes of ARVs.1 The incorporation of
human IgG2 heavy chain increases the half-life and minimises
potential for immunogenicity of the protein. PRO 542 is able
to neutralise primary viral isolates in vivo. A phase I study of
HIV-infected adults using single doses of 25 mg/kg of PRO 542
demonstrated acute reductions in viral load, which continued
for 4 - 6 weeks.2 A small 4-week monotherapy paediatric study
of weekly infusions of 10 mg/kg demonstrated a decline in
viral load of > 0.7 log10 copies/ml , which was sustained for 14
days post-therapy, in 4 of 6 subjects. 
CHEMOKINE RECEPTOR INHIBITORS
HIV binds initially to its target cell via the gp120/CD4
interaction but also requires the presence of human
membrane CCR5 or CXCR4 co-receptors. CCR5 is the co-
receptor utilised by the most commonly transmitted
macrophage-tropic HIV strains, which predominate in early
HIV-infection. It has been recognised that individuals with a
32-CCR5 homozygous phenotype lack a functional CCR5
receptor and are resistant to HIV infection. It is postulated that
effective CCR5 inhibition would be able to reproduce this
cellular resistance to HIV infection. The assays used to
determine HIV co-receptor tropism are complex and expensive
and currently lack the sensitivity to identify minority
populations of CXCR4 using virus. However, these assays have
been utilised in cross-sectional studies of receptor tropism to
show increasing use of the CXCR4 with disease progression.
CXR4 tropic viruses are usually associated with increased CD4
cell destruction. In vitro and in vivo data to date indicate that
CCR5 inhibition does not lead to change in viral tropism, but
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Highly active antiretroviral therapy (HAART) has to date been based on use of a triple combination of drugs chosen from three
classes of antiretrovirals (ARVs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs) and protease inhibitors (PIs). These ARV classes target two of the three virally encoded enzymes necessary
for viral replication after entry of HIV into the host cell. A greater understanding of the viral-host interactions necessary for
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the third viral enzyme encoded by the pol gene, has remained an elusive target. Compounds with low toxicity and able to inhibit
(IN) are now entering phase II clinical development. These new HIV treatment modalities represent a significant advance in and
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can result in expansion of pre-existing minority species of
dual-tropic (CCR5/CXCR4) and monotropic (CXCR4)
subpopulations. Evolution of HIV co-receptor binding can also
occur in absence of CXCR4 variants.
UK-427,857 is a CCR5 inhibitor which has shown dose-related
antiviral activity in 80 ART-naïve individuals with pre-
dominately CCR5 tropic virus with doses of up to 300 mg bid,
which were well tolerated. Doses of ≥ 100 mg bid and qd
resulted in viral load reductions of ≥ 1 log10 when given as
short-term monotherapy. Dosing with food did not have a
significant effect on the antiviral efficacy. The viral load did
not rebound immediately upon cessation of the drug,
indicating that a proportion of receptors remain blocked for
some time.3 Receptor-binding modelling studies indicate that
a dose of 100 mg bd or equivalent daily dose will be necessary
for long-term treatment.4 Recent studies have shown that
resistance to UK-427,857 probably emerges slowly, but is not
always associated with loss of use of the CCR5 co-receptor.5
SCH-D is a piperazine-based CCR5 antagonist unrelated to
SCH-C, from which it has taken over as a lead compound.
SCH-D has greater in vitro and in vivo potency than SCH-C,
which has been withdrawn from further clinical development.
When SCH-D binds to the CCR5 receptor, there is a
conformation change that prevents HIV gp120 binding. SCH-
D does not induce CYP3A4 and has an elimination half-life of
24 hours. In a randomised study of 48 patients receiving 10,
25 or 50 mg SCH-D twice daily or placebo, the maximum viral
load reduction occurred in the 50 mg group: by day 15, viral
load had fallen by a mean of 1.5 log10, compared with 1 log10
in the 10 mg group and no change from baseline in the
placebo group.6 The proportions achieving a viral load
reduction  greater than 1.5 log10 were similar in the 25 and 50
mg groups (46% v. 45%). There was only one adverse event
possibly related to the drug (fever).
GSK-873140 is a spirodiketopiperizine CCR5 antagonist with
potent in vitro activity. In HIV-infected individuals with CD4
cell counts > 200 µl and predominately CCR5 tropic virus at
baseline, a dose-related antiviral
effect was shown. After 10 days,
mean viral load decline varied
between –0.4 log10 with 200 mg od
to –1.6 log10 with 600 mg bd. The
commonest adverse events were
gastrointestinal.7
AMD-070 is an investigational
CXCR4 receptor inhibitor. In vitro it
prevented CXCR4 monotropic and
CCR5/CXCR4 bitropic HIV strains
from infecting peripheral blood
mononuclear cells (PBMCs). When
combined with a CCR5 receptor
inhibitor, no viral replication of any
of the viral strains tested occurred
in PBMCs.8
FUSION INHIBITORS
T-20, or enfurvitide, is the first fusion inhibitor approved by
the FDA for treatment of HIV infection in patients failing
existing therapies.9 T-20 protein is a linear 36 amino acid
corresponding to a sequence within HR2, and acts
extracellularly at nanomolar concentrations. T-20 binds to HRI,
thereby inhibiting its interaction with its natural ligand (gp41
HR2) necessary for the contraction of gp41 and drawing
together of the viral and target membranes. Mutations in the
HR1 region of gp41 can result in resistance to T-20; however
there is no evidence of cross-resistance to other ARVs
including the newer fusion inhibitors under development. HIV-
1 isolates resistant to NRTIs, NNRTIs and PIs are susceptible to
T-20 in vitro. The peptide is not an inducer of CYP3A4 and no
clinically significant pharmacological interactions have been
reported with other ARVs. The usual dosage of T-20 is 90 mg
(1 ml) administered by subcutaneous injection twice daily, and
T-20 should be augmented with other potent drugs. The
formulation is a lyophilised powder, which is dissolved in
sterile water before use and should be refrigerated and used
within 24 hours. Irritation at the injection site is the
commonest adverse event and hypersensitivity reactions are
rare (< 1%). An increase in bacterial pneumonia was observed
in trial patients receiving T-20 compared with those receiving
placebo, but the causation was uncertain. T-20 has a role in
salvage therapy of heavily pretreated individuals, but its
manufacture is complex, requiring multiple steps, and it is
likely to remain a costly drug. 
T-1249 is a second-generation fusion inhibitor, which has
greater in vitro potency than T-20 and has activity against
viral strains resistant to T-20. The drug is a 39-amino acid
peptide from a hybrid of sequences of HIV-1, HIV-2 and SIV
peptides, which is administered as a subcutaneous injection
once or twice daily. The optimal dose for T-1249 has not been
determined. Adverse events include irritation at the injection
site, hypersensitivity and neutropenia. Monotherapy studies in
heavily pretreated patients demonstrated a 1.3 log10 decline in
viral load after 14 days with a 25 mg twice-daily dose. In a 10-
day study of 54 individuals with resistance to T-20 switching


























Fig. 1B. Mechanisms of action of three
classes of entry inhibitors.
A. Attachment inhibitor e.g. PRO 542 links to gp120 and
inhibits binding to CD4 receptor.
B. CCR5 co-receptor inhibitor e.g. UK 427,857, SCH-D or
GSK-873140 prevent binding of gp120 to co-receptor.
C. Fusion Inhibitor e.g. T-20 binds to HR-1 and prevents
cross-linkage to HR-2.
HR-1
A. Initial contact between viral extra-membrane protein
gp120 and target cell CD4 receptor.
B. HIV gp120 binding to human co-receptor CCR5 or
CXCR4.
C. Helical region 1 (HR-1) binds to helical region 2 (HR-
2) of viral transmembrane protein gp41, leading to
conformation change and apposition of viral and cell
membranes prior to fusion.
Fig. IA. Interactions between viral gp120
and cellular receptors leading to conforma-
tional changes in transmembrane protein
gp41 and fusion of HIV and cell membranes.
THE SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE                                         november 2005 51
achieved a 1 log10 drop in viral load.
10 Those who had been on
T-20 for less than 48 weeks had a better response than those
who had had more than 48 weeks’ therapy. T-1249
development was discontinued in January 2005 because of
formulation problems.
INTEGRASE INHIBITORS
Integration of a DNA copy of the viral genome into the host
cell chromosome is necessary for latent HIV-infection to be
established. The process is catalysed by integrase (IN), a 288
amino acid molecule encoded by the 3‘-end of the pol gene.
Integration is a multi-stepped process (Fig. 2) including
formation of an DNA-IN complex by IN recognition of specific
sequences in the long terminal repeat of viral retro-transcribed
DNA; 3‘ processing by removal of the terminal GT nucleotides
from 3‘-end; translocation of the DNA-IN complex from the
cytoplasm through the nuclear pore; strand transfer into the
host DNA by joining of the 3‘-end of double-strand viral DNA
to the 5‘-end of host DNA strands at a staggered cleavage 5
nucleotides apart; and finally repair of the junctions by host
cellular DNA repair machinery. The end result of these processes
is a full-length cDNA insertion of the viral genome, flanked by
two identical 5-nucleotide sequences of host DNA. IN has
remained an elusive target of drug development, for although
a number of compounds have been shown to inhibit this
enzyme in vitro many of them have shown high toxicity.
Recently IN inhibitors have been identified which act by
inhibiting either DNA binding or strand transfer. 
S-1360 is a diketo acid (DKA) derivative displaying anti-HIV
activity at micro-molar concentrations. The DKAs represent the
first class of IN inhibitors specifically inhibiting the DNA strand
transfer step of the integration process (INSTI). Multiple
passage of virus in presence of S-1360 resulted in selection of
strains resistant to S-1360 associated with the sequential
acquisition of mutations of the integrase gene.11 S-1360 is
orally bioavailable and was generally well tolerated in a phase
I study of single doses up to 2 000 mg and twice-daily dosing
up to 2 000 mg for 11 days, in healthy volunteers.
V-165, a dipyrimidine derivative, is an ‘IN-DNA binding inhibitor’
(INBI) which constitutes a second class of integrase inhibitor.
Studies of the mechanism of action of V-165 indicate inhibition
of the formation of the IN-DNA complex. DKA-resistant HIV
strains remained sensitive to in vitro inhibition by V-165.
SUMMARY
ARV therapy remains a rapidly evolving field, which 
has paralleled the expanding knowledge of the HIV life cycle
and greater understanding of the complex interactions
between host and pathogen. The hold on development of 
T-1240 illustrates that even very promising lead candidates
can be lost at later stages of the development pipeline.
However, the increasing number of new compounds and the
development of completely new targets improves our ability to
counter the high mutability of HIV and develop new antiviral
strategies. Attachment inhibition, for example, may offer a
logical target for aborting HIV infection after exposure. T-20,
the first of the new class of entry inhibitors, already has an
established role in salvage therapy. Inhibition of  gp120/CCR5
binding is particularly exciting because the target is the first to
be encoded by the host rather than the viral genome. The
ability to pharmacologically reproduce the 32-CCR5
homozygous phenotype may also eventually give us a
modality that can be used in early HIV infection, when CCR5
variants are predominant. Combinations of CCR5 and CXCR4
inhibitors may be needed to have activity later in HIV disease
progression and the use of combinations of two classes of IN
inhibitors would increase the genetic barrier required to
overcome inhibitors of this third HIV enzyme target.
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Fig. 2. Steps required for HIV DNA integration into the human
genome.
A. Formation of integrase-DNA (IN-DNA) complex by IN binding to long terminal repeat (LTR)
region of viral DNA.
B. IN 3 end processing of LTR and transport of IN-DNA complex through nuclear pore.
C. IN staggered splicing at random site in human chromosome.
D. IN strand transfer by joining of 3 LTR with 5 end of spliced human DNA.
E. DNA repair by nuclear enzymes; removal of 5 terminal viral AC nucleotides and repair of
spliced chromosome DNA. Result: integrated provirus flanked by identical five nucleotide
sequences.
